Oncoinvent ASA (OB: ONCIN)
Health Care · Pharmaceuticals · NO
Nkr83.80
-7.30% today · -24.0% 1Y
Oncoinvent ASA (OB: ONCIN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $42.89M and employs 44 people.
Over the last twelve months the share price has lost 24.0%, trading between 40.10 and 134.80.
Tweenvest scores Oncoinvent ASA across four factors: quality 28/100, growth 100/100. Its strongest factor is growth.
ONCIN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.89M
- Revenue (TTM)
- $2.78M
- P/E
- —
- EPS
- -125.13
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- Nkr134.80
- 52-week low
- Nkr40.10
- Avg volume (3M)
- —
- Shares outstanding
- 4.48M
- Employees
- 44
- Next earnings
- —
About Oncoinvent ASA
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
- Listed since
- Apr 7, 2017
- Exchange
- Oslo Bors
- Currency
- NOK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.